Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?

por Walenga, Jeanine M.
Publicado 2022

Why differentiate low molecular weight heparins for venous thromboembolism?

por Fareed, Jawed, Walenga, Jeanine M
Publicado 2007

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

por Prechel, M Margaret, Walenga, Jeanine M
Publicado 2013

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin

por Jeske, Walter, Walenga, Jeanine M, Hoppensteadt, Debra, Fareed, Jawed
Publicado 2013

Heparan sulphate inhibition of cell proliferation induced by TGFβ and PDGF

por Silber, lan E., Walenga, Jeanine M., Fareed, Jawed, Kovacs, Elizabeth J.
Publicado 1993

Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

por Prechel, Margaret, Hudec, Susan, Lowden, Elizabeth, Escalante, Vicki, Emanuele, Nicholas, Emanuele, Maryann, Walenga, Jeanine M.
Publicado 2018

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

por McClane, Nathan, Jeske, Walter, Walenga, Jeanine M., Escalante, Vicki, Hoppensteadt, Debra, Schwartz, Jeffrey, Bakhos, Mamdouh
Publicado 2018

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

por Walenga, Jeanine M., Torres, Tania A., Jeske, Walter P., Schwartz, Jeffrey, Escalante, Vicki, Newman, Joshua D., Bakhos, Mamdouh
Publicado 2020

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

por Kantarcioglu, Bulent, Iqbal, Omer, Walenga, Jeanine M., Lewis, Bruce, Lewis, Joseph, Carter, Charles A., Singh, Meharvan, Lievano, Fabio, Tafur, Alfonso, Ramacciotti, Eduardo, Gerotziafas, Grigoris T., Jeske, Walter, Fareed, Jawed
Publicado 2021